Skip to main content

Table 2 The incidence of VBIs among children with maternal HBsAg positivity during follow-up

From: A booster hepatitis B vaccine for children with maternal HBsAg positivity before 2 years of age could effectively prevent vaccine breakthrough infections

Timepoint of VBIs detection

VBIs, n (%)

Type of VBIs

Anti-HBc ( +) alone, n (%)

Overt HBV infection, n (%)

Occult HBV infection, n (%)

Overall, (454)

 2 years of age

14 (3.08%)

7 (1.54%)

0

7 (1.54%)

 3 years of age

3 (0.66%)

3 (0.66%)

0

0

 5 years of age

14 (3.08%)

7 (1.54%)

7 (1.54%)

0

 Total

31 (6.83%)

17 (3.74%)

7 (1.54%)

7 (1.54%)

Nonbooster groupa, (252)

 2 years of age

14 (5.56%)

7 (2.78%)

0

7 (2.78%)

 3 years of age

3 (1.19%)

3 (1.19%)

0

0

 5 years of age

13 (5.16%)

6 (2.38%)

7 (2.78%)

0

 Total

30 (11.90%)

16 (6.35%)

7 (2.78%)

7 (2.78%)

Booster group, (202)

 2 years of age

0

0

0

0

 3 years of age

0

0

0

0

 5 years of age

1 (0.50%)

1 (0.50%)

0

0

 Total

1 (0.50%)

1 (0.50%)

0

0

  1. aSix children who experienced HBV VBIs before receiving a booster HepB were included in the nonbooster group